On the 10th February 2004, subsequent to disquiet amongst the ME/CFS
community in relation to the criteria being used for the PACE trial,
Mr. Chris Clark CEO of Action for ME (AfME) issued this statement:


THE PACE TRIAL

"ACTION FOR M.E. STATEMENT

I note that there has been some comment on the e-groups regarding the
criteria for the PACE study. Some time ago the researchers agreed at
our request to also record all those in the study against BOTH the Fukuda
criteria and the operationalised criteria for myalgic
encephalomyelitis.

It is intended that this should provide information on whether any of
the treatments being compared are more helpful or more harmful than the
othersfor different definitions of CFS / M.E.

Chris Clark
Chief Executive"